Associação entre haplótipos de metaloproteinase-9 de matriz extracelular (MMP-9) e obesidade infantil : efeitos sobre a concentração plasmática de MMP-9 / Association between haplotypes of matrix metalloproteinase-9 extracellular matrix (MMP-9) and childhood obesity : effects on plasma concentration of MMP-9

AUTOR(ES)
DATA DE PUBLICAÇÃO

2011

RESUMO

The childhood obesity is important risk factor for cardiovascular diseases, in particular, atherosclerose. This condition is characterized by the accumulation of lipids and fibrous elements in the large arteries in which inflammatory mechanisms and vascular remodeling are involved. In this context, matrix metalloproteinase 9 (MMP-9) - endopeptidade capable of degrading components of extracellular matrix - and its endogenous inhibitor preferential, the tissue inhibitors of MMP (TIMP-1) are important mediators of this remodeling and a critical equilibrium between MMP-9 and TIMP-1 must exist in order to maintain the integrity of cardiovascular system. Moreover, elevated levels of MMP-9 have been reported in patients with cardiovascular diseases, and genetic studies showing that functional polymorphism MMP-9 gene were related to presence and severity of cardiovascular diseases. However, it remains unclear how the association of these polymorphisms with childhood obesity can affect MMP-9 plasma concentrations. Thus, the objectives of this study were: 1) to compare plasma MMP-9, TIMP-1 and MMP-9/TIMP-1(activity) ratio between obese and control groups; 2) to compare the genotype and haplotype frequencies of MMP-9 polymorphisms (C-1562T and (CA)14-24 and Q279R) between obese and control and, 3) correlate the MMP-9 concentrations with MMP-9 genotypes and haplotypes. To achieve our first goal, we determined the plasma pro-MMP-9 levels by zymography, and plasma MMP-9 and TIMP-1 concentrations by ELISA in obese and control. We not found differences in MMP-9 plasma concentratios and MMP-9/TIMP-1 between obese and control. However, our results showed that obese had lower plasma TIMP-1 concentrations than control. Moreover, to achieve our second goal, we firstly extracted DNA from volunteers, and then we determined the genotype frequencies of C-1562T and (CA)14-24 polymorphisms by PCR followed by electrophoresis, of and Q279R polymorphism by real time PCR, and the haplotype frequencies by the programs PHASE. We found similar genotype and allelic distribution for the three polymorphisms when study groups were compared. We evaluated the relevance of different genotypes in plasma MMP-9 concentrations in study groups. To the C-1562T and Q279R polymorphisms, we found that in the obese group, CC genotype carries had lower MMP-9 levels when compared with CT+TT genotype carries and control with the same genotype. In the obese group, QQ genotype carries had lower MMP-9 levels when compared with RR genotype carries and control the same genotype. To the -90(CA)14-24 polymorphism, we did not observe differences in the MMP-9 levels among different genotypic groups. In relation to haplotypes, we found that in the obese group, H2 haplotype carriers had lower MMP-9 levels and MMP-9/TIMP-1 ratio when compared other haplotypes and control with the same haplotype. Therefore, our findings suggest that (CC and QQ) genotypes and H2 haplotype decrease circulating MMP-9 levels in obese but not in healthy children, thus genotypes and haplotype could offer protection against cardiovascular diseases in those children

ASSUNTO(S)

metaloproteinase da matriz polimorfismo haplótipos farmacogenética aterosclerose matrix metalloproteinase polymorphism haplotype pharmacogenetic atherosclerosis

ACESSO AO ARTIGO

Documentos Relacionados